Circulating MicroRNA-214 and -126 As Potential Biomarkers for Canine Neoplastic Disease

Overview

Journal Sci Rep

Specialty Science

Date 2017 May 25

PMID 28536479

Citations 32

Authors

Kazuki Heishima

Yukie Ichikawa

Kyoko Yoshida

Ryota Iwasaki

Hiroki Sakai

Takayuki Nakagawa

Yuiko Tanaka

Yuki Hoshino

Yasuhiko Okamura

Mami Murakami

Kohji Maruo

Yukihiro Akao

Takashi Mori

Affiliations

Soon will be listed here.

Abstract

Circulating microRNAs in the blood may provide diagnostic and prognostic information about canine neoplastic diseases, and their profiles may be conserved between human and canine species. We performed RT-qPCR to obtain the profiles of circulating plasma microRNA-214 and -126 in total 181 cases of canine neoplastic diseases and healthy controls. MicroRNA-214 levels were high in 2 epithelial tumours (thyroid and mammary carcinomas) and 4 non-epithelial tumours (osteosarcoma, histiocytic sarcoma, chondrosarcoma, and hemangiosarcoma). In contrast, microRNA-126 levels were high in 6 epithelial tumours (mammary, hepatocellular, squamous cell, thyroid, transitional cell carcinomas, and adenocarcinoma) and 4 non-epithelial tumours (osteosarcoma, mast cell tumour, melanoma, and hemangiosarcoma). The diagnostic potential of microRNA-214 was relatively high in sarcomas, whereas that of microR-126 was high in most types of the tumours. MicroRNA-214 and -126 were prognostic predictors in 2 groups (adenocarcinoma and non-epithelial tumours except for osteosarcoma) and 3 groups (epithelial tumours, adenocarcinoma, and melanoma), respectively. Additionally, the microRNA levels did not show a strong correlation with the other clinical parameters. In conclusion, circulating microRNA-214 and -126 have the potential to be diagnostic and prognostic biomarkers for canine neoplastic diseases. Furthermore, their profiles may be key references as well for exploring novel biomarkers for human cancers.

Citing Articles

Epigenetic regulation in muscle-invasive urothelial carcinoma of the bladder in the dog, a translational model of human cancer.

Tsamouri M, Kent M, Mudryj M, Ghosh P Vet Oncol. 2025; 1.

PMID: 39944718 PMC: 11815638. DOI: 10.1186/s44356-024-00011-2.

Plasma microRNA signatures predict prognosis in canine osteosarcoma patients.

Ludwig L, Edson M, Treleaven H, Viloria-Petit A, Mutsaers A, Moorehead R PLoS One. 2024; 19(12):e0311104.

PMID: 39739708 PMC: 11687810. DOI: 10.1371/journal.pone.0311104.

DR-70 (fibrinogen-fibrin degradation products) as a prognostic biomarker in dogs with neoplasms.

Ke C, Lin C, Sio K, Wu C, Xia Y, Lee J Vet Q. 2024; 44(1):1-10.

PMID: 39028259 PMC: 11262238. DOI: 10.1080/01652176.2024.2380049.

Exploring the role of microRNAs as diagnostic and prognostic biomarkers in canine mammary tumors.

Ferreira T, Gil da Costa R, Dias F, Gama A, Gaspar V, Mano J Geroscience. 2024; 46(6):6641-6657.

PMID: 38954129 PMC: 11494623. DOI: 10.1007/s11357-024-01260-7.

MicroRNAs and angiosarcoma: are there promising reports?.

Modarresi Chahardehi A, Afrooghe A, Emtiazi N, Rafiei S, Rezaei N, Dahmardeh S Front Oncol. 2024; 14:1385632.

PMID: 38826780 PMC: 11143796. DOI: 10.3389/fonc.2024.1385632.

References

Kinoshita T, Yip K, Spence T, Liu F . MicroRNAs in extracellular vesicles: potential cancer biomarkers. J Hum Genet. 2016; 62(1):67-74. DOI: 10.1038/jhg.2016.87. View

van Balkom B, de Jong O, Smits M, Brummelman J, den Ouden K, de Bree P . Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells. Blood. 2013; 121(19):3997-4006, S1-15. DOI: 10.1182/blood-2013-02-478925. View

Heishima K, Mori T, Ichikawa Y, Sakai H, Kuranaga Y, Nakagawa T . MicroRNA-214 and MicroRNA-126 Are Potential Biomarkers for Malignant Endothelial Proliferative Diseases. Int J Mol Sci. 2015; 16(10):25377-91. PMC: 4632806. DOI: 10.3390/ijms161025377. View

Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L . The dog as a cancer model. Nat Biotechnol. 2006; 24(9):1065-6. DOI: 10.1038/nbt0906-1065b. View

Hao M, Zang M, Zhao L, Deng S, Xu Y, Qi F . Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget. 2016; 7(15):19589-600. PMC: 4991403. DOI: 10.18632/oncotarget.7319. View

Zhang Z, Li Y, Wang H, Fu S, Wang X, Zeng M . Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma. PLoS One. 2014; 9(1):e86149. PMC: 3897649. DOI: 10.1371/journal.pone.0086149. View

Fletcher R . Carcinoembryonic antigen. Ann Intern Med. 1986; 104(1):66-73. DOI: 10.7326/0003-4819-104-1-66. View

Jiang Y, Wang H, Li Y, Guo S, Zhang L, Cai J . Peripheral blood miRNAs as a biomarker for chronic cardiovascular diseases. Sci Rep. 2014; 4:5026. PMC: 4052773. DOI: 10.1038/srep05026. View

Schoffski P, Cornillie J, Wozniak A, Li H, Hompes D . Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. Oncol Res Treat. 2014; 37(6):355-62. DOI: 10.1159/000362631. View

10.

Turchinovich A, Burwinkel B . Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol. 2012; 9(8):1066-75. PMC: 3551861. DOI: 10.4161/rna.21083. View

11.

Kosaka N, Iguchi H, Ochiya T . Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010; 101(10):2087-92. PMC: 11159200. DOI: 10.1111/j.1349-7006.2010.01650.x. View

12.

Dai D, Lu Q, Huang Q, Yang P, Hong B, Xu Y . Serum miRNA signature in Moyamoya disease. PLoS One. 2014; 9(8):e102382. PMC: 4122349. DOI: 10.1371/journal.pone.0102382. View

13.

Schwarzenbach H, Milde-Langosch K, Steinbach B, Muller V, Pantel K . Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat. 2012; 134(3):933-41. DOI: 10.1007/s10549-012-1988-6. View

14.

Steinberg W, Gelfand R, Anderson K, Glenn J, Kurtzman S, Sindelar W . Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology. 1986; 90(2):343-9. DOI: 10.1016/0016-5085(86)90930-3. View

15.

Camp R, Dolled-Filhart M, Rimm D . X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10(21):7252-9. DOI: 10.1158/1078-0432.CCR-04-0713. View

16.

Olivieri F, Spazzafumo L, Bonafe M, Recchioni R, Prattichizzo F, Marcheselli F . MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. Oncotarget. 2015; 6(34):35372-82. PMC: 4742111. DOI: 10.18632/oncotarget.6164. View

17.

Wei X, Han M, Yang F, Wei G, Liang Z, Yao H . Biological significance of miR-126 expression in atrial fibrillation and heart failure. Braz J Med Biol Res. 2015; 48(11):983-9. PMC: 4671524. DOI: 10.1590/1414-431X20154590. View

18.

Pfeffer S, Grossmann K, Cassidy P, Yang C, Fan M, Kopelovich L . Detection of Exosomal miRNAs in the Plasma of Melanoma Patients. J Clin Med. 2015; 4(12):2012-27. PMC: 4693157. DOI: 10.3390/jcm4121957. View

19.

Wang K, Yuan Y, Cho J, McClarty S, Baxter D, Galas D . Comparing the MicroRNA spectrum between serum and plasma. PLoS One. 2012; 7(7):e41561. PMC: 3409228. DOI: 10.1371/journal.pone.0041561. View

20.

Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X . Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2009; 127(1):118-26. DOI: 10.1002/ijc.25007. View